Ū

đ Ū

ř.

N

rnev Docket P1777R1



CERTIFICATION UNDER 37 CFR 1.10

EL 599583895 US: Express Mail Number

October 27, 2000: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION **Assistant Commissioner of Patents** Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Brigitte Devaux, Redwood City, California Gilbert-Andre Keller, Belmont, California Hartmut Koeppen, Berkeley, California Laurence A. Lasky, Sausalito, California

Title: **Anti-Tumor Antibody Compositions and Methods of Use**

- 1. **Type of Application**
- [] This application is for an original, non-provisional application.
- [X] This is a non-provisional application claiming priority to provisional application no. 60/162,558, filed October 29, 1999, and 60/182,872, filed February 16, 2000 the entire disclosure of which is hereby incorporated by reference.
- This is a [] continuation-in-part [] continuation [] divisional application claiming priority to application Serial Number___, filed ____, the entire disclosure of which is hereby incorporated by reference.
- 2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)
 - 74 pages of specification
 - 3 pages of claims
 - page(s) of abstract
 - sheet(s) of drawings

[X] formal [] informal

3.	Declaration or Oath
	(for new and CIP applications; also for Cont./Div. where inventor(s) are being added) X An executed declaration of the inventor(s) [] is enclosed [X] will follow.
	(for Cont./Div. where inventorship is the same or inventor(s) being deleted) A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).
	(for Cont./Div. where inventor(s) being deleted) A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).
4 .	Assignment
	(for new and CIP applications) X An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [X] will follow.
	(for cont./div.) The prior application is assigned of record to Genentech, Inc.
5.	Amendments (for continuation and divisional applications)
	Cancel in this application original claims of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
	A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)
	Relate Back 35 U.S.C. 120 or 35 U.S.C. 119
	Amend the specification by inserting before the first line the sentence:
	This is a
•	non-provisional application continuation divisional continuation-in-part
	of co-pending application(s)
	Serial No filed on_, which application(s) is(are) incorporated herein by reference and to

	which application(s) priority is claimed under 35 USC §120 International Application _ filed on _ which designated the U.S., which application(s) is(are
	incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120
	provisional application No filed _, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC \$119

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

		CLAIM	S FOR FEE CA	LCULATION	
		and a summer of the	er Extra	New Johnson Control	Basic Fee 37 CFR 1.16(a)
		la a calabana a sa sa sa	i daga kan kan kan kan kan kan kan kan kan ka	The second of the second of the	\$710.00
Total Claims	57	- 20 =	37	X \$18.00	\$738.00
Independent Claims	3	- 3=	0	X \$80.00	\$0.00
X	Multiple d	ependent claim	(s), if any	+ \$270.00	\$270.00
			Fili	ng Fee Calculation	\$1,718.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$1,718.00. A duplicate copy of this transmittal is enclosed.

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. <u>A duplicate copy of this sheet is enclosed.</u>

9. Additional Papers Enclosed

- [] Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- [X] Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- [] A new Power of Attorney or authorization of agent.
- [] Other:

10.	Maintenance of Copendency of Prior Application (for continuation and divisional applications)
	[This item must be completed and the necessary papers filed in the prior application if the period set
	in the prior application has run]

A petition, fee and/or response has been filed to extend the term i

the pending prior application until A copy of the petition for extension of time in the *prior* application is attached.

Correspondence Address: 11.

Address all future communications to: <u>X</u>

> GENENTECH, INC. Attn: Lee K. Tan 1 DNA Way South San Francisco, CA 94080-4990 (650) 225-4462

> > Respectfully submitted, GENENTECH, INC.

Date: October 27, 2000

lle Tan Reg. No. 39,447

1 DNA Way So. San Francisco, CA 94080-4990 Phone: (650) 225-4462

Fax: (650) 952-9881